NCT06924359Recruiting
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 6 Apr 2025
- Start date
- 19 Mar 2025
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Peking University First Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT06924359
What you commit to
- Study type: Observational
- Planned participants: 200
- From 19 Mar 2025 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
Other
- Inability to cooperate with cognitive assessments;
- Refusal to undergo blood sampling.
Who the study is looking for
- Male or female participants aged ≥ 50 years;
- Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
- Signed informed consent form
Age in the registry: 50 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.